Literature DB >> 21384431

Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.

Ralf Ihl1, Steven Ferris, Philippe Robert, Bengt Winblad, Serge Gauthier, Frank Tennigkeit.   

Abstract

OBJECTIVE: When complex cognitive functions are measured with multi-item scales like the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-cog), it seems valuable information can be lost due to combination of the ADAS-cog items results into a total score. We hypothesized, that an analysis of the results of different ADAS-cog item combinations may reveal drug treatment effects in distinct cognitive domains and/or enhance the sensitivity to detect such treatment effects. Here, we present a novel approach called 'subsetting analysis' for assessment of drug treatment effects with multi-item scales, like the ADAS-cog.
METHODS: The subsetting approach is a mathematical algorithm designed to select and group scale items in a subset detecting drug treatment effects in a particular study population. The approach was applied in a post-hoc analysis of ADAS-cog results from two randomized, placebo-controlled and double-blind clinical trials with memantine in mild to moderate Alzheimer's disease (AD). The subsetting analysis of the ADAS-cog combined database aimed at selecting the scale items showing no worsening at study end compared to baseline due to memantine treatment in mild AD (Mini-Mental State Examination (MMSE >19)) patients.
RESULTS: Two ADAS-cog subsets were finally revealed by the analysis: a subset of five ADAS-cog items, identified as most sensitive to memantine effects in mild AD patients, and a subset of six ADAS-cog items shown to detect significant memantine effects in moderate AD patients.
CONCLUSION: The subsetting approach of analyzing ADAS-cog data is a powerful alternative for gaining information about drug effects on cognitive performance in mild and moderate AD patients.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21384431     DOI: 10.1002/gps.2679

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  6 in total

1.  The Alzheimer's Disease Assessment Scale-Cognitive-Plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI.

Authors:  Jeannine Skinner; Janessa O Carvalho; Guy G Potter; April Thames; Elizabeth Zelinski; Paul K Crane; Laura E Gibbons
Journal:  Brain Imaging Behav       Date:  2012-12       Impact factor: 3.978

2.  Neurostimulation for cognitive enhancement in Alzheimer's disease (the NICE-AD study): a randomized clinical trial.

Authors:  Emma Gulley; Joe Verghese; Helena M Blumen; Emmeline Ayers; Cuiling Wang; Russell K Portenoy; Jessica L Zwerling; Erica Weiss; Helena Knotkova
Journal:  Neurodegener Dis Manag       Date:  2021-07-09

3.  Adding Chinese herbal medicine to conventional therapy brings cognitive benefits to patients with Alzheimer's disease: a retrospective analysis.

Authors:  Jing Shi; Jingnian Ni; Tao Lu; Xuekai Zhang; Mingqing Wei; Ting Li; Weiwei Liu; Yongyan Wang; Yuanyuan Shi; Jinzhou Tian
Journal:  BMC Complement Altern Med       Date:  2017-12-13       Impact factor: 3.659

Review 4.  The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): Modifications and Responsiveness in Pre-Dementia Populations. A Narrative Review.

Authors:  Jacqueline K Kueper; Mark Speechley; Manuel Montero-Odasso
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Effects of Molecular Hydrogen Assessed by an Animal Model and a Randomized Clinical Study on Mild Cognitive Impairment.

Authors:  Kiyomi Nishimaki; Takashi Asada; Ikuroh Ohsawa; Etsuko Nakajima; Chiaki Ikejima; Takashi Yokota; Naomi Kamimura; Shigeo Ohta
Journal:  Curr Alzheimer Res       Date:  2018-03-14       Impact factor: 3.498

6.  The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial.

Authors:  Mo Li; Ji-Hui Lyu; Yi Zhang; Mao-Long Gao; Wen-Jie Li; Xin Ma
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.